Beck Bode, LLC Abb Vie Inc. Transaction History

Beck Bode, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$154.79 - $180.76 $6.68 Million - $7.8 Million	43,175 New	43,175 $7.41 Million
Q2 2022 Jul 29, 2022	BUY	$137.62 - $174.96 $1.3 Million - $1.65 Million	9,433 New	9,433 $1.45 Million
Q4 2021 Feb 07, 2022	SELL	$107.43 - $135.93 $4.36 Million - $5.52 Million	-40,610 Closed	0 $0
Q3 2021 Oct 22, 2021	SELL	$106.4 - $120.78 $20,322 - $23,068	-191 Reduced 0.47%	40,610 $4.38 Million
Q2 2021 Jul 29, 2021	BUY	$105.21 - $117.21 $4.29 Million - $4.78 Million	40,801 New	40,801 $4.6 Million
Q1 2021 May 10, 2021	SELL	$102.3 - $112.62 $61,380 - $67,572	-600 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$85.91 - $100.83 $168,984 - $198,332	-1,967 Reduced 76.63%	600 $53,000
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $3,154 - $4,221	43 Added 1.7%	2,567 $252,000
Q1 2020 May 14, 2020	BUY	$64.5 - $97.79 $162,798 - $246,821	2,524 New	2,524 $207,000
Q1 2019 Nov 27, 2019	SELL	$77.14 - $90.79 $1.65 Million - $1.94 Million	-21,381 Closed	0 $0
Q4 2018 Nov 27, 2019	BUY	$77.85 - $96.01 $1.66 Million - $2.05 Million	21,381 New	21,381 $1.97 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Beck Bode, LLC, based on Form 13F filings with the SEC.

Stay updated on Beck Bode, LLC with notifications on news.